Engineered variants of human glutamic acid decarboxylase (GAD) and autoantibody epitope recognition

• Published in: Clinical immunology (Orlando, Fla.) Fla.), 2003-07, Vol.108 (1), p.38-45
• Main Authors: Primo, M.E, Anton, E.A, Villanueva, A.L, Poskus, E, Ermácora, M.R
• Format: Article
• Language: English
• Subjects: Autoantibodies; Autoantibodies - immunology; Autoimmune thyroid disease; Autoimmunity; Biological and medical sciences; Diabetes; Diabetes Mellitus, Type 1 - immunology; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Epitopes; Epitopes - immunology; Etiopathogenesis. Screening. Investigations. Target tissue resistance; GAD65 protein; Glutamate Decarboxylase - genetics; Glutamate Decarboxylase - immunology; Glutamic acid decarboxylase; Humans; Medical sciences; Protein Engineering; Radioimmunoassay; Recombinant protein
• ISSN: 1521-6616; 1521-7035
• DOI: 10.1016/S1521-6616(03)00061-5

Of the two homologous forms of glutamic acid decarboxylase, GAD65 and GAD67, only GAD65 is a common target of autoimmunity. Epitope profiles of autoantibodies to GAD65 (GADA) in 140 type 1 diabetes, adult-onset diabetes mellitus (AODM), and thyroid diseases (TD) were studied. Probes were GAD65, GAD65/67 hybrids (displaying separately GAD65 residues 1–95, 96–444, and 445–585), δGAD65 (a truncated GAD65 spanning residues 69–585), and GAD67. δGAD65 and GAD65 detected 137 and 125 positive patients, respectively. The hybrids reacted with 113 sera and in 3 cases disclosed cryptic epitopes. Eighteen patients reacted with GAD67, indicating GAD65-GAD67 cross-reactivity. Most patients recognized both middle and C-terminal epitopes, had low reactivity against N-terminal epitopes, and seldom displayed reactivity limited to the N or C terminus. Compared with type 1 and AODM, TD patients showed a greater prevalence of multiple reactivity and higher incidence of GAD67 positivity.